Table 1.
Clinical characteristics of PD-MCI subtypes
| Amnestic Single- domain N=24 |
Amnestic Multiple- domain N=31 |
Nonamnestic Single- domain N=61 |
Nonamnestic Multiple- domain N=12 |
p value |
|
|---|---|---|---|---|---|
| Age, years | 72.79 (10.57) | 71.81 (6.83) | 70.51 (10.88) | 76.50 (6.01) | 0.24 |
| Male, n (%) | 16 (66.7) | 20 (64.5) | 32 (52.5) | 8 (66.7) | 0.51 |
| Education, years | 15.50 (3.67) | 14.39 (3.01) | 14.26 (2.48) | 15.25 (3.02) | 0.37 |
| PD duration, years | 5.54 (4.13) | 7.06 (4.04) | 7.64 (5.16) | 9.04 (7.18) | 0.19 |
| UPDRS total motor score | 28.43 (11.46) | 31.83 (11.07) | 29.97 (12.08) | 36.42 (11.07) | 0.24 |
| Hoehn & Yahr stage (median, range) | 2.0, 2–4 | 2.0, 2–5 | 3, 1–4 | 3, 2–5 * | 0.04 |
| Vascular risk factor score (median, range) | 1.0, 0–5 | 1.0, 0–4 | 1.0, 0–4 | 1.5, 0–3 | 0.57 |
| LEDD, mg/d | 375.63 (308.42) | 524.84 (368.89) | 550.33 (552.65) | 753.96 (438.20) | 0.14 |
| Agonist, n (%) | 6 (25.0) | 10 (32.3) | 24 (39.3) | 4 (33.3) | 0.65 |
| Mood medication (antidepressant/anxiolytic), n (%) | 8 (33.3) | 14 (45.2) | 21 (34.4) | 0 (0) + | 0.05 |
| Sleep medication, n (%) | 4 (16.7) | 5 (16.1) | 9 (14.8) | 3 (25.0) | 0.86 |
| Antipsychotic, n (%) | 3 (12.5) | 3 (9.7) | 1 (1.6) | 1 (8.3) | 0.21 |
| Cognitive medication, n (%) | 2 (8.3) | 7 (22.6) | 4 (6.6) | 0 (0) | 0.06 |
Data presented as mean (SD), unless otherwise noted.
Abbreviations: LEDD, levodopa equivalent daily doses; UPDRS, Unified Parkinson’s Disease Rating Scale.
*
Nonamnestic multiple-domain vs. Amnestic single-domain PD-MCI, p=0.04;
+
Nonamnestic multiple-domain vs. Amnestic multiple-domain PD-MCI, p=0.03